COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,164 Articles (22,703 medRxiv, 8,461 bioRxiv)

Most recent first Previous |  Page 103: Articles 1021-1030  | Next

Evidence suggests that the SARS-CoV-2 Spike (S) protein may target coiled-coil regions of numerous cytoskeletal and cytoskeleton-associated proteins
Brezellec, P.
10.1101/2025.01.20.633897 — Posted: 2025-01-21
Tryptophan metabolism reprogramming contributes to the prothrombotic milieu in mice and humans infected with SARS-CoV-2
Subramaniam, S., Napoleon, M. A., Lotfollahzadeh, S., Kamal, M. H., Kurniawan, H., Elsadawi, M., Kenney, D., Dhouam, F., Bosmann, M., Whelan, S., Cabral, H., Burks, E. J., Zhao, G., Kolachalama, V., Ravid, K., Chitalia, V.
10.1101/2025.01.17.633602 — Posted: 2025-01-21
Genetic markers of enhanced functional antibody responses to COVID-19 vaccination
Purcell, R. A., Aurelia, L. C., Allen, L. F., Bond, K. A., Williamson, D. A., Trevillyan, J. M., Trubiano, J. A., Wines, B. D., Hogarth, P. M., Juno, J. A., Wheatley, A. K., Nguyen, T. H., Subbarao, K., Kedzierska, K., Kent, S. J., Mahanty, S., John Selva, K., Chung, A. W.
10.1101/2025.01.20.25320822 — Posted: 2025-01-20
A phylogenetic method identifies candidate drivers of the evolution of the SARS-CoV-2 mutation spectrum
Corbett-Detig, R.
10.1101/2025.01.17.633662 — Posted: 2025-01-20
GALILEO Generatively Expands Chemical Space and Achieves One-Shot Identification of a Library of Novel, Specific, Next Generation Broad-Spectrum Antiviral Compounds at High Hit Rates
Umansky, T., Woods, V., Russell, S. M., Garvey, D. S., Smith, D. M., Haders, D.
10.1101/2025.01.17.633620 — Posted: 2025-01-20
Modular DNA Barcoding of Nanobodies Enables Multiplexed in situ Protein Imaging and High-throughput Biomolecule Detection
Zhong, S., Wang, R., Gao, X., Guo, Q., Lin, R., Luo, M.
10.1101/2025.01.16.633477 — Posted: 2025-01-20
Optimizing Transfection Efficiency in Primary Human Splenic Fibroblast Cells
Kaur, A., Assogba, V. I., Assogba, B. D.
10.1101/2025.01.19.633792 — Posted: 2025-01-20
SARS-CoV-2 neutralizing antibody specificities differ dramatically between recently infected infants and immune-imprinted individuals
Dadonaite, B., Burrell, A. R., Logue, J., Chu, H. Y., Payne, D. C., Haslam, D. B., Staat, M. A., Bloom, J. D.
10.1101/2025.01.17.633612 — Posted: 2025-01-20
Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus-MPro inhibitors with potent in vivo efficacy
Detomasi, T. C., Degotte, G., Huang, S., Suryawanshi, R., Diallo, A., Lizzadro, L., Zapatero-Belinchon, F., Taha, T. Y., Li, J., Richards, A., Hantz, E., Alam, Z., Montano, M., Malvido, M., Gumpena, R., Partridge, J. R., Correy, G. J., Carvat, A., Glenn, I. S., Rosencrans, J., Revalde, J., Anderson, D., Hultquist, J. F., Arkin, M. R., Neitz, J., Swaney, D. L., Krogan, N. J., Shoichet, B., Verba, K., Ott, M., Renslo, A., Craik, C. S.
10.1101/2025.01.16.633443 — Posted: 2025-01-18
Receipt of BNT162b2 KP.2 Vaccine and COVID-19 CVS MinuteClinic Visits in US Adults
Rudolph, A. E., Khan, F. L., Sun, X., Lupton, L. L., Puzniak, L. A., Jodar, L., McLaughlin, J. M.
10.1101/2025.01.15.24319342 — Posted: 2025-01-17

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).